Excellamol
- Biotech or pharma, therapeutic R&D
Excellamol develops polypeptide-drug conjugates for patients with rare pediatric diffuse midline glioma and adult glioblastoma. To date, Excellamol has invested a total of $1 million, resulting in two Orphan Drug Designations and a candidate for Rare Pediatric Disease Designation, and is now launching a Series A financing round to support Phase 0/1 clinical trials.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}